Matrix metalloproteinases in carcinoma of unknown primary

Cancer. 2005 Nov 15;104(10):2282-7. doi: 10.1002/cncr.21454.

Abstract

Background: The purpose was to study proteolysis-related molecules, matrix metalloproteinase-2 (MMP-2) and MMP-9 and tissue inhibitor of metalloproteinases-1 (TIMP-1), in carcinoma of unknown primary (CUP).

Methods: Paraffin-embedded tumor material from 75 patients diagnosed with CUP was used. Tumor histologies were adenocarcinoma (77%), undifferentiated carcinoma (19%), and squamous cell carcinoma (4%) and patients were categorized into favorable (62%) and unfavorable (38%) subsets. The tissue expression of MMP-2, MMP-9, and TIMP-1 was assessed by use of specific monoclonal antibodies and evaluated by means of a visual staining score. The expression of molecules studied was analyzed against clinicopathological data.

Results: MMP-2 was found expressed in 69% (strong expression in 49%), MMP-9 in 49% (strong in 36%), and TIMP-1 in 79% (strong in 44%) of studied cases. The expression of MMP-2 correlated positively with MMP-9. TIMP-1 was significantly higher in unfavorable compared with favorable tumors and was associated with a shorter survival of patients (7.5 vs. 12 mos). No other associations were detected.

Conclusions: MMP-2, MMP-9, and TIMP-1 are widely expressed in CUP, suggesting an essential role of proteolysis in these tumors. TIMP-1 may be considered a possible marker of poor prognosis in CUP patients.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / analysis
  • Carcinoma / enzymology*
  • Carcinoma / secondary*
  • Female
  • Humans
  • Immunohistochemistry
  • Male
  • Matrix Metalloproteinases / metabolism*
  • Middle Aged
  • Neoplasms, Unknown Primary / enzymology*
  • Prognosis
  • Tissue Inhibitor of Metalloproteinases / metabolism

Substances

  • Biomarkers, Tumor
  • Tissue Inhibitor of Metalloproteinases
  • Matrix Metalloproteinases